DAIICHI SANKYO COMPANY,LIMITED (4568.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

19.1x

EV/EBITDA

15.6x

Market Cap

JPY 5.28T

MomentumView details →

1D Return

−0.99%

YTD Return

−16.55%

RSI (14)

49.6

ValuationView details →

P/E (Fwd)

19.1x

EV/EBITDA

15.6x

Market Cap

JPY 5.28T

RSI (14)

49.6

MomentumView details →

1D Return

−0.99%

YTD Return

−16.55%

ProfitabilityView details →

Gross Margin

68.49%

Net Margin

12.24%

EBITDA Margin

14.44%

ROE (TTM)

15.62%

ROA (TTM)

6.49%

Asset Turnover

0.54x

GrowthView details →

Revenue YoY

+12.55%

EPS YoY

−9.71%

FCF YoY

+18.76%

Revenue CAGR 3Y

+18.42%

EPS CAGR 3Y

+35.10%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.18x

Current Ratio

2.42x

Quick Ratio

1.64x

Div Yield

2.73%

Div Rate

JPY 78.00

Div Growth 1Y

+30.00%

Financials snapshotView financials →

Revenue (TTM)

2.12T

Net Income (TTM)

259.87B

Op. CF (TTM)

77.66B

Next earningsOct 30, 2026 →

Latest newsMore news →

Daiichi Sankyo's market capitalization fell about 55% from its peak in July 2024 to 5.3707 trillion yen as of September 2, 2026, dropping it to fourth place among Japanese pharmaceutical companies.2d ago

Daiichi Sankyo announced that the European Union granted a partial change approval for the combination therapy of Enhertu and pertuzumab as first-line treatment for breast cancer patients.3d ago

Similar companies

Astellas Pharma Inc.4503.T Otsuka Holdings Co.,Ltd.4578.T Takeda Pharmaceutical Company Limited4502.T Shionogi & Co.,Ltd.4507.T CHUGAI PHARMACEUTICAL CO.,LTD.4519.T Eisai Co.,Ltd.4523.T Find similar companies →

Latest newsMore news →

Daiichi Sankyo's market capitalization fell about 55% from its peak in July 2024 to 5.3707 trillion yen as of September 2, 2026, dropping it to fourth place among Japanese pharmaceutical companies.2d ago Daiichi Sankyo announced that the European Union granted a partial change approval for the combination therapy of Enhertu and pertuzumab as first-line treatment for breast cancer patients.3d ago Daiichi Sankyo announced that its drug Enhertu (trastuzumab deruxtecan) in combination with pertuzumab received approval in China for first-line treatment of unresectable or metastatic HER2-positive breast cancer in adults.23d ago